ヨーロッパのオメガ3脂肪酸による精神病のリスクが非常に高い被験者を対象としたプラセボ対照試験 (PURPOSE)
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
調査の概要
詳細な説明
PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 14 sites in 9 countries.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Edinburgh、イギリス
- Psychiatry, Centre for Clinical Brain Sciences
-
-
-
-
-
Petah Tikva、イスラエル
- Schneider Children's Medical Center
-
Ramat Gan、イスラエル
- Tel Hashomer The Sheba Medical Center
-
-
-
-
-
Rome、イタリア
- Fondazione Santa Lucia
-
Rome、イタリア
- Sapienza University of Rome
-
-
-
-
-
Utrecht、オランダ
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht
-
-
-
-
-
Vienna、オーストリア
- BioPsyC Biopsychosocial Corporation
-
-
-
-
-
Zurich、スイス
- ZKJP University Zürich
-
-
-
-
-
Barcelona、スペイン
- Hospital Clinic de Barcelona
-
Barcelona、スペイン
- Hospital Infantil Passeig Sant Joan de Deu
-
Madrid、スペイン
- Hospital General Universitario Gregorio Marañon
-
Santander、スペイン
- Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria
-
-
-
-
-
Tübingen、ドイツ
- Department of Child and Adolescent Psychiatry, University of Tübingen
-
-
-
-
-
Bergen、ノルウェー
- Institute of Clinical Medicine, University of Bergen
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Written informed consent of the subject. For individuals younger than 18 years of age the parents / legal representatives need to give consent, and the subject can provide assent (whether the latter is required depends on local laws and regulations).
- UHR diagnosis as made using the Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic symptoms (a history of one or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) either the presence of schizotypal personality disorder or a family history of psychosis in a first-degree relative, all three together with a recent decline in function.
Exclusion Criteria:
- Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial.
- Laboratory screening values considered clinically relevant by a medical doctor for transaminases, thyroid hormones or coagulation parameters
- Current or past DSM-IV diagnosis of psychosis, as measured with K-SADS-PL
- Current treatment with an antipsychotic or mood-stabilising agent
- Intake of an antipsychotic or mood-stabilising agent in the two weeks prior to study inclusion
- Intake of an antipsychotic agent equivalent to a total haloperidol use of >50 mg in the six months prior to study inclusion
- A first-degree relative (i.e. parents, offspring or siblings) participating in this study
- UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely explained by acute intoxication
- Current aggression or dangerous behaviour (PANSS G14 score 5 or above)
- Current suicidality / self-harm (PANSS G6 score 7)
- Current DSM-IV diagnosis of alcohol or substance dependence as measured with K-SADS-PL
- Any current or previous neurological disorder, including epilepsy
- History of head injury resulting in unconsciousness lasting at least 1 hour
- IQ < 70
- More than 4 weeks of regular omega-3 supplementation (>2 daily capsules standard strength providing >600 mg combined EPA/DHA) within the last 6 months.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Omega-3 fatty acids
Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months. |
他の名前:
|
|
プラセボコンパレーター:Placebo
Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Transition Rate
時間枠:measured starting from baseline up to 2 years post-baseline
|
To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition). |
measured starting from baseline up to 2 years post-baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Discontinuation Rate
時間枠:measurement starting at baseline up to 2 years post-baseline
|
how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline) |
measurement starting at baseline up to 2 years post-baseline
|
|
Symptomatology
時間枠:baseline to 2 years post-baseline
|
change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms. |
baseline to 2 years post-baseline
|
|
Psychosocial Functioning
時間枠:measurement started at baseline up to the 2 year timepoint
|
Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning. |
measurement started at baseline up to the 2 year timepoint
|
|
Intelligence
時間枠:One time assessment of IQ
|
This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning |
One time assessment of IQ
|
|
Blood Levels of Bioactive Lipids
時間枠:measurement started at baseline up until 6 months
|
Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline. |
measurement started at baseline up until 6 months
|
|
Positive and Negative Symptoms
時間枠:from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms. |
from baseline to 2 years post-baseline
|
|
Level of Functioning
時間枠:from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning. |
from baseline to 2 years post-baseline
|
|
Level of Depression
時間枠:measured starting at baseline up to 2 years post-baseline
|
Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms. |
measured starting at baseline up to 2 years post-baseline
|
|
Role Functioning
時間枠:measurement started at baseline up until 2 years post-baseline
|
Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction. |
measurement started at baseline up until 2 years post-baseline
|
|
Social Functioning
時間枠:measurement started at baseline up until 2 years post-baseline
|
Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation. |
measurement started at baseline up until 2 years post-baseline
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:René Kahn, Prof. Dr.、UMC Utrecht
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。